Get the Stockscreener App
8.01
0.50%
-0.04
After Hours:
7.67
-0.34
-4.24%
Ocular Therapeutix Inc stock is traded at $8.01, with a volume of 501.92K.
It is down -0.50% in the last 24 hours and down -11.20% over the past month.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
See More
Previous Close:
$8.05
Open:
$8.15
24h Volume:
501.92K
Relative Volume:
0.54
Market Cap:
$1.26B
Revenue:
$61.10M
Net Income/Loss:
$-138.36M
P/E Ratio:
-5.9333
EPS:
-1.35
Net Cash Flow:
$-90.59M
1W Performance:
-2.44%
1M Performance:
-11.20%
6M Performance:
+0.12%
1Y Performance:
+93.01%
1-Day Range:
$7.99
$8.18
1-Week Range:
$7.695
$8.43
52-Week Range:
$3.7599
$11.78
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Name
Ocular Therapeutix Inc
Sector
Industry
Phone
781-357-4000
Address
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
8.01 | 1.26B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-20-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Feb-09-24 | Initiated | BofA Securities | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Aug-10-22 | Resumed | Berenberg | Buy |
| Aug-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-28-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Nov-13-20 | Reiterated | Raymond James | Strong Buy |
| Aug-10-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| May-21-19 | Downgrade | Cowen | Outperform → Market Perform |
| May-21-19 | Reiterated | H.C. Wainwright | Buy |
| May-21-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-03-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-18 | Initiated | Raymond James | Strong Buy |
| Sep-07-18 | Initiated | Piper Jaffray | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-26-17 | Initiated | H.C. Wainwright | Buy |
| Jul-12-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jun-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-10-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | RBC Capital Mkts | Outperform |
| Aug-11-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-17-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-23-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-13-15 | Initiated | Morgan Stanley | Overweight |
View All
Ocular Therapeutix Inc Stock (OCUL) Latest News
Advancements in Ocular Hypertension Clinical Trial Pipeline - GlobeNewswire
Ocular Therapeutix (NASDAQ:OCUL) and Verona Pharma (NASDAQ:VRNA) Financial Contrast - Defense World
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ocular Therapeutix Grants Stock Options and RSU Awards to New Employee in Incentive Plan - StockTitan
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Ocular Therapeutix (STU:0OT) Cash From Discontinued Investi - GuruFocus.com
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR - GlobeNewswire
Ocular Therapeutix progresses with AXPAXLI trials for eye diseases By Investing.com - Investing.com Canada
Ocular Therapeutix progresses with AXPAXLI trials for eye diseases - Investing.com India
Ocular Therapeutix Advances AXPAXLI Eye Treatment Trials with Strong Enrollment Milestone - StockTitan
Neuropathic Ocular Pain Market Is Booming Worldwide 2025-2032 | - openPR
Investors push Ocular Therapeutix (NASDAQ:OCUL) 6.3% lower this week, company's increasing losses might be to blame - Simply Wall St
Learn to Evaluate (OCUL) using the Charts - Stock Traders Daily
OCULOcular Therapeutix, Inc. Latest Stock News & Market Updates - StockTitan
Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation - The Manila Times
Ocular Therapeutix™ to Provide Corporate Update During 43rd - GlobeNewswire
Ocular Therapeutix CEO to Present AXPAXLI Trial Updates at J.P. Morgan Healthcare Conference - StockTitan
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Principal Financial Group Inc. - Defense World
EyePoint initiated at buy by Citi on wAMD drug potential - MSN
Ocular Stock Is Now Thoroughly Derisked (NASDAQ:OCUL) - Seeking Alpha
Long Term Trading Analysis for (OCUL) - Stock Traders Daily
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Geode Capital Management LLC - MarketBeat
Geode Capital Management LLC Has $28.46 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix (NASDAQ:OCUL) Shares Down 2.5%Time to Sell? - MarketBeat
State Street Corp Has $30.24 Million Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Barclays PLC Has $4.45 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
State Street Corp Trims Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Last Week's Biggest Stock Movers: Mylan, Ocular Therapeutix - AOL
Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week - Yahoo Finance
How to Take Advantage of moves in (OCUL) - Stock Traders Daily
Wellington Management Group LLP Purchases 148,310 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
BNP Paribas Financial Markets Sells 19,513 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix Insiders Sold US$1.0m Of Shares Suggesting Hesitancy - Simply Wall St
Fmr LLC Purchases 428,335 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix Grants Major Stock Awards Package to New Executive, Including 285K Shares - StockTitan
Verition Fund Management LLC Purchases Shares of 62,501 Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Ocular Therapeutix CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Charles Schwab Investment Management Inc. Has $9.66 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Point72 Asset Management L.P. Trims Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
492,900 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Bought by Polar Asset Management Partners Inc. - MarketBeat
HC Wainwright Reaffirms Buy Rating for Ocular Therapeutix (NASDAQ:OCUL) - Defense World
235,498 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Purchased by Patient Square Capital LP - MarketBeat
Erste Asset Management GmbH Makes New $2.05 Million Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Keratoconus Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix - Barchart
Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts - Inkl
Ocular Therapeutix Inc Stock (OCUL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):